Almotriptan
From Wikipedia, the free encyclopedia
Almotriptan
|
|
Systematic (IUPAC) name | |
N,N-dimethyl-2- [5-(pyrrolidin-1-ylsulfonylmethyl)- 1H-indol-3-yl]-ethanamine | |
Identifiers | |
CAS number | |
ATC code | N02 |
PubChem | |
DrugBank | |
Chemical data | |
Formula | C17H25N3O2S |
Mol. mass | 335.465 g/mol |
Pharmacokinetic data | |
Bioavailability | 70% |
Protein binding | 35% |
Metabolism | ? |
Half life | 3-4 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
C(USA) |
Legal status | |
Routes | Oral |
Almotriptan (Axert®, Almogran®) is a triptan drug discovered by Almirall Prodesfarma and licensed to Ortho-McNeil for the treatment of migraine headaches. It is available in strengths of 6.25 and 12.5 mg as a tablet.
In the United States and Canada almotriptan is available under the name Axert® only by prescription. AXERT® for oral administration contains almotriptan malate equivalent to 6.25 or 12.5 mg of almotriptan. Each compressed tablet contains the following inactive ingredients: mannitol, cellulose, povidone, sodium starch glycolate, sodium stearyl fumarate, titanium dioxide, hypromellose, polyethylene glycol, propylene glycol, iron oxide (6.25 mg only), FD&C Blue No. 2 (12.5 mg only), and carnauba wax. The brand Almogran is used in Belgium, Finland, France, Germany, Italy, Portugal, Spain and the United Kingdom. Each 12.5 mg. tablet contains the following inactive ingredients: carnauba wax, hypromellose, indigo carmine (E132), macrogol 400, mannitol, microcrystalline cellulose, povidone, propylene glycol, sodium starch glycollate, sodium stearyl fumarate and titanium dioxide (E171).
[edit] Clinical uses
Almotriptan is indicated for the acute treatment of migraine with or without aura in adults.
[edit] External links
- R&D page by Almirall Prodesfarma
- Axert Official homepage by Ortho-McNeil
- Axert prescribing information
|